Identification and management of cardiometabolic risk in Canada: A position paper by the cardiometabolic risk working group (Executive summary)

Canadian Journal of Cardiology

Volumn 27, Issue 2, 2011, Pages 124-131

  Leiter, Lawrence A ^a,b   Fitchett, David H ^a,b   Gupta, Richard E Gilbert ^a,b,c,d   Mancini, G B John ^e   McFarlane, Philip A ^a,c   Ross, Robert ^f   Verma, Subodh ^a,b   Anand, Sonia ^a,b   Camelon, Kathryn ^g   Chow, Chi Ming ^a,b   Cox, Jafna L ^h   Després, Jean Pierre ⁱ   Genest, Jacques ^j   Harris, Stewart B ^k   Lau, David C W ^l   Lewanczuk, Richard ^m   Liu, Peter P ^b,c   Lonn, Eva M ^c   McPherson, Ruth ⁿ   Poirier, Paul ^h   Qaadri, Shafiq ^o   Rabasa Lhoret, Rémi ^p   Rabkin, Simon W ^c   Sharma, Arya M ^m   Steele, Andrew W ^q   Stone, James A ^l   Tardif, Jean Claude ^r   Tobe, Sheldon ^b,s   Ur, Ehud ^e   more..

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c University of Queensland   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ UNIVERSITÉ LAVAL   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k UNIVERSITY OF WESTERN ONTARIO   (Canada)

^l UNIVERSITY OF CALGARY   (Canada)

^m UNIVERSITY OF ALBERTA   (Canada)

ⁿ UNIVERSITY OF OTTAWA   (Canada)

^o Institut de Recherches Cliniques de Montréal ^*

^p CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^q LAKERIDGE HEALTH CORPORATION   (Canada)

^r UNIVERSITÉ DE MONTRÉAL   (Canada)

^s SUNNYBROOK RESEARCH INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; AMFEBUTAMONE; AMLODIPINE; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; LISINOPRIL; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; VALSARTAN; VARENICLINE;

ANTICOAGULANT THERAPY; ARTICLE; ATHEROGENIC DIET; BARIATRIC SURGERY; CANADA; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE PREDISPOSITION; ETHNICITY; GLUCOSE BLOOD LEVEL; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HUMAN; HYPERGLYCEMIA; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; NICOTINE REPLACEMENT THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROPHYLAXIS; RISK MANAGEMENT; SMOKING CESSATION; WEIGHT REDUCTION; INCIDENCE; METHODOLOGY; OBESITY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

CANADA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; METABOLIC SYNDROME X; OBESITY; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 79958065049     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.01.016     Document Type: Article

References (64)

1. Leiter LA, Fitchett DH, Gilbert RE, et al, for the Cardiometabolic Risk Working Group. Cardiometabolic risk in Canada: a detailed analysis and position paper by the Cardiometabolic Risk Working Group. Can J Cardiol 2011; 27: e1-e33.
2. Daly CA, Hildebrandt P, Bertrand M, et al. for the EUROPA investigators. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 2007; 93:1406-11.
3. Mellen PB, Cefalu WT, Herrington DM. Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2006;26:189-93.
4. Nilsson PM, Engström G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects: a populationbased study comparing three different definitions. Diabet Med 2007;24: 464-72.
5. Nilsson PM. Cardiovascular risk in the metabolic syndrome: fact or fiction? Curr Cardiol Rep 2007;9:479-85.
6. Galassi A, Reynolds K, He J. Metabolic syndrome and the risk of cardiovascular disease: a meta-analysis. Am J Med 2006;119:812-9.
7. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and metaanalysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-14.
8. Noto D, Barbagallo CM, Cefalù AB, et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. Atherosclerosis 2008;197:147-53.
9. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30:8-13.
10. de Simone G, Devereux RB, Chinali M, et al, for the Strong Heart Study Investigators. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care 2007;30:1851-6.
11. Arnlov J, Ingelsson E, Sundstrom J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010;121:230-6.
12. Després J-P, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arteroscler Thromb Vasc Biol 2008;28:1039-49.
13. Mente A, Yusuf S, Islam S, et al. Metabolic syndrome and risk of acute myocardial infarction: a case-control study of 26 903 subjects from 52 countries. J Am Coll Cardiol 2010;55:2390-8.
14. Després J-P, Tchernof A. Classification of overweight and obesity. In: 2006 Canadian clinical practice guidelines on management and prevention of obesity in adults and children. CMAJ 2007;176:Online-21-6. Available at: http://www.cmaj.ca/cgi/data/176/8/S1/DC1/1. Accessed January 20, 2011.
15. Després J-P, Cartier A, Côté M, Arsenault BJ. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med 2008;40:514-23.
16. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després J-P. Visceral obesity and the heart. Int J Biochem Cell Biol 2008;40:821-36.
17. Poirier P, Alpert MA, Fleisher LA, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation 2009;120:86-95.
18. Poirier P, Eckel RH. Cardiovascular consequences of obesity. Drug Discov Today: Ther Strategies 2008;5:45-51.
19. Poirier P, Lemieux I, Mauriège P, et al. Impact of waist circumference on the relationship between blood pressure and insulin. The Quebec Health Survey. Hypertension 2005;45:363-7.
20. Poirier P. Healthy lifestyle: even if you are doing everything right, extra weight carries an excess risk of acute coronary events. Circulation 2008; 117:3057-9.
21. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
22. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
23. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA, American Heart Association; National Heart, Lung, and Blood Institute. Clinical management of metabolic syndrome: report of the American Heart Association/ National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551-6.
24. Lau DC, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007;176:S1-13.
25. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(suppl 1):S1-201.
26. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25:567-79.
27. Canadian Hypertension Education Program. Recommendations 2010. Available at: http://hypertension.ca/chep/recommendations-2010/. Accessed September 13, 2010.
28. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Examination Survey (NHAMES III), National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52: 1210-4.
29. Sharma AM, Douketis JD. Pharmacotherapy for obesity: adults. In: 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007;176:online 66-71. Available at: http://www.cmaj.ca/cgi/data/176/8/S1/DC1/1. Accessed January 20, 2011.
30. James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-17.
31. US Food and Drug Administration. Follow-up to the November 2009 early communication about an ongoing safety review of sibutramine, marketed as Meridia. Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm198206.htm. Accessed September 13, 2010.
32. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61.
33. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.
34. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351,2683-93.
35. Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract 2008;14(suppl 1):1-83.
36. Holman R, Haffner S, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362: 1463-76.
37. DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008;31:1007-14.
38. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8.
39. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
40. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-7.
41. Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-13.
42. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.
43. ACCORD Investigators. Effects of combination lipid therapy in type 2 diabetes mellitus. N Eng J Med 2010;362:1563-74.
44. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
45. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
46. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
47. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94.
48. DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
49. DeFronzo R. ACTos NOW for the prevention of diabetes (ACT NOW) study. Oral presentation at: American Diabetes Association 68th Scientific Sessions. June 9, 2008, San Francisco, CA.
50. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010; 376:103-11.
51. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
52. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-13.
53. Anand SS, Yusuf S, Vuksan V, et al, for the SHARE Investigators. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000;356:279-84.
54. Liu J, Hanley AJ, Young TK, Harris SB, Zinman B. Characteristics and prevalence of the metabolic syndrome among three ethnic groups in Canada. Int J Obes (Lond) 2006;30:669-76.
55. WHOExpert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363(9403):157-63.
56. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
57. Yusuf S, Hawken S, Ounpuu S, et al, for the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): casecontrol study. Lancet 2004;364:937-52.
58. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99: 410-14.
59. Health Canada. Association of CRESTOR (rosuvastatin) with musclerelated adverse events - AstraZeneca Inc. Available at: http://www.hcsc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2005/crestor_2_pa-apeng.php. Accessed September 13, 2010.
60. FDA Public Health Advisory on Crestor (rosuvastatin). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ PublicHealthAdvisories/ucm051756.htm. Accessed February 25, 2011.
61. Gupta M, Braga MF, Teoh H, Tsigoulis M, Verma S. Statin effects on LDL and HDL cholesterol in South Asian and white populations. J Clin Pharmacol 2009;49:831-7.
62. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008;371:1927-35.
63. Sattar N. The metabolic syndrome: should current criteria influence clinical practice? Curr Opin Lipidol 2006;17:404-11.
64. American Diabetes Association. Understanding Cardiometabolic Risk: Broadening Risk Assessment and Management. Alexandria, VA: American Diabetes Association; 2007.